(R)-N-甲基-2-吡咯烷-1-甲基-吡咯烷 | 76411-80-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (R)-N-甲基-2-吡咯烷-1-甲基-吡咯烷
• 中文别名: (S)-1-甲基-2-(1-吡咯烷基甲基)吡咯烷
• 英文名称: (S)-N-methyl-2-[(pyrrolidin-1-yl)methyl]pyrrolidine
• 英文别名: (S)-1-methyl-2-<(pyrrolidin-1-yl)methyl>pyrrolidine；(S)-1-methyl-2-(pyrrolidin-1-ylmethyl)pyrrolidine；(2S)-1-methyl-2-(pyrrolidin-1-ylmethyl)pyrrolidine
• CAS: 76411-80-8
• 化学式: C₁₀H₂₀N₂
• 分子量: 168.282
• InChiKey: QXYPUAXZYCLIJM-JTQLQIEISA-N

物化性质

• 沸点：
  214℃
• 密度：
  0.971
• 闪点：
  76℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  苯丙酮 、 (R)-N-甲基-2-吡咯烷-1-甲基-吡咯烷 以66%的产率得到
  参考文献：
  名称：

  IWASAWA, NOBUHARU;MUKAIYAMA, TERUAKI, CHEM. LETT., 1982, N 9, 1441-1444

  摘要：

  DOI：
• 作为产物：
  描述：

  (2R,5S)-2-trichloromethyl-1-aza-3-oxabicyclo[3.3.0]octan-4-one 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 1.0h， 生成 (R)-N-甲基-2-吡咯烷-1-甲基-吡咯烷
  参考文献：
  名称：

  Synthesis of chiral diamines using novel 2-trichloromethyloxazolidin-4-one precursors derived from 5-oxo-proline and proline

  摘要：

  Efficient syntheses of chiral vicinal diamines derived from (S)-oxo-proline and (S)-proline are described. The novel diastereomerically pure precursor (2R,5S)-2-trichloromethyl-1-aza-3-oxabicyclo-[3.3.0]-octan-4,8-dione 3 and its enantiomer are readily available by reaction of the inexpensive enantiomers of 5-oxo-proline with chloral. Compound 3 reacts with primary and secondary amines to afford the 5-oxo-prolylamides 4 in quantitative yield. In contrast, the (S)-proline-derived precursor (2R,5S)-2-trichloromethyl-1-aza-3-oxabicyclo[3.3.0]octan-4-one 6 gave (S)-N-formylprolylamides 9 and/or (S)-prolylamides 8 depending on the reaction conditions. Upon reduction with LiAlH4, amides 4 and 9 afforded the proline-derived (S)-2-(alkylaminomethyl)pyrrolidines 1 and (S)-N- methyl-2-(alkylaminomethyl)-pyrrolidines 5 in 70-90% yields. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(02)00579-7
• 作为试剂：
  描述：

  丁烯酮 、 4-氰基苯甲醛 在 (R)-N-甲基-2-吡咯烷-1-甲基-吡咯烷 作用下， 以 乙醇 为溶剂， 反应 96.0h， 生成 (S)-3-[hydroxy(4-cyanophenyl)methyl]but-3-en-2-one 、 (R)-3-[hydroxy(4-cyanophenyl)methyl]but-3-en-2-one
  参考文献：
  名称：

  手性二胺介导的不对称Baylis-Hillman反应

  摘要：

  容易从脯氨酸制备的手性二胺是醛和甲基乙烯基酮的Baylis-Hillman反应的有效，不对称有机催化剂，提供的对映选择性高达75％。

  DOI：

  10.1002/adsc.200404069

文献信息

• METHODS FOR PREPARING DPP-IV INHIBITOR COMPOUNDS
  申请人：Ronsheim Matthew

  公开号：US20100240611A1

  公开（公告）日：2010-09-23

  Methods for preparing an inhibitor of dipeptidyl peptidase IV, as well as formulations of such inhibitors of dipeptidyl peptidase IV that have a high degree of stability including under warm, humid storage conditions.

  制备二肽基肽酶IV抑制剂的方法，以及具有高度稳定性的二肽基肽酶IV抑制剂的配方，包括在温暖潮湿的储存条件下。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20090240045A1

  公开（公告）日：2009-09-24

  A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 , R 3 , R 4 and W are as defined herein.

  式(I)的化合物，或其立体异构体或药学上可接受的盐，以及它们的制备和用作药物，其中R1、R2、R3、R4和W的定义如本文所述。
• ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF
  申请人：Ohno Michihiro

  公开号：US20100016319A1

  公开（公告）日：2010-01-21

  This invention relates to a pharmaceutical comprising as an effective ingredient an arylmethylene urea exemplified by the following formula: or a pharmaceutically acceptable salt thereof. The arylmethylene urea and the pharmaceutically acceptable salts thereof are useful for therapy or prophylaxis of inflammatory bowel disease and overactive bladder.

  本发明涉及一种药物，其有效成分为以下式子所示的芳基亚甲基脲或其药学上可接受的盐： 该芳基亚甲基脲及其药学上可接受的盐可用于治疗或预防炎症性肠病和过度活跃的膀胱。
• AMIDE DERIVATIVE OR SALT THEREOF
  申请人：Kaku Hidetaka

  公开号：US20090062363A1

  公开（公告）日：2009-03-05

  [Problem] To provide a compound which can be used for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that an amide derivative characterized by the possession of a nitrogen-containing bicyclic hetero ring (e.g., an indole or the like), or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT 2B receptor and 5-HT 7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).

  [问题] 提供一种可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病的化合物，特别是用于治疗肠易激综合征（IBS）。 [解决方法] 发现一种具有含氮双环杂环（例如吲哚或类似物）的酰胺衍生物或其药学上可接受的盐具有强烈的5-HT2B受体和5-HT7受体的拮抗作用。此外，本发明的化合物具有对两种受体的拮抗活性，与仅使用选择性拮抗剂相比，表现出良好的药理作用。基于上述，本发明的化合物可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病，特别是用于治疗肠易激综合征（IBS）。